Tykerb and Herceptin work better together, study suggests
This article was originally published in Scrip
Executive Summary
Using GlaxoSmithKline's Tykerb/Tyverb (lapatinib) and Roche's Herceptin (trastuzumab) together to treat breast cancer has better results than treatment with either drug alone, suggests a study published in The Lancet today.